SOUTH SAN FRANCISCO, Calif., June 10, 2026
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) and Tecentriq Hybreza® in combination with chemotherapy for the adjuvant treatment of patients with Stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer following surgery. The FDA is expected to make its approval decision by October 9, 2026. The filing is supported by positive results from the pivotal Phase III ATOMIC trial, which demonstrated a significant reduction in disease recurrence and mortality risk, potentially positioning the immunotherapy-based regimen as a new standard of care for patients with this high-risk form of colon cancer.
Phase III ATOMIC Trial Demonstrates Significant Clinical Benefit
The FDA’s Priority Review designation is based on findings from the landmark ATOMIC Phase III study, which evaluated Tecentriq in combination with standard FOLFOX6 chemotherapy in patients with Stage III dMMR colon cancer. Results showed that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone. The study also reported a 36-month disease-free survival rate of 86% in patients receiving the Tecentriq combination regimen versus 76% among patients treated with chemotherapy alone.
These findings represent a substantial advancement in the treatment of early-stage colon cancer, particularly for patients with tumors characterized by high mutation rates and increased responsiveness to immunotherapy. The safety profile observed in the study remained consistent with previously established data for Tecentriq and FOLFOX6, reinforcing confidence in the treatment approach.
Addressing a Major Unmet Need in Early Colon Cancer
Advertisement
Colon cancer remains one of the most frequently diagnosed and deadly cancers worldwide, with more than one million new cases reported annually. Despite surgery and adjuvant chemotherapy, approximately 30% of Stage III colon cancer patients experience disease recurrence within five years, highlighting the urgent need for more effective treatment strategies. Approximately 15% of colon cancer patients have dMMR/MSI-H tumors, a biomarker-defined subgroup associated with high mutation burden and increased sensitivity to immune checkpoint inhibitors.
By targeting the PD-L1 pathway, Tecentriq helps reactivate the body’s immune response against cancer cells, offering a precision medicine approach tailored to tumor biology. Industry experts believe the successful integration of immunotherapy into the adjuvant setting could transform treatment outcomes and improve long-term survival rates for thousands of patients globally.
FDA Review Could Establish New Standard of Care
The Priority Review designation underscores the potential significance of Tecentriq in the evolving landscape of gastrointestinal oncology. The ATOMIC trial, sponsored by the National Cancer Institute and conducted through the Alliance for Clinical Trials in Oncology in collaboration with Genentech and international research partners, represents one of the most important studies evaluating immunotherapy in early-stage colon cancer. If approved, Tecentriq plus chemotherapy could become the first immunotherapy-based adjuvant treatment option specifically indicated for Stage III dMMR/MSI-H colon cancer, establishing a new benchmark for personalized cancer care after surgery.
The regulatory milestone further strengthens Genentech’s oncology portfolio and highlights the growing role of biomarker-driven treatment strategies in improving outcomes across multiple cancer types. With the FDA decision expected later this year, oncologists and patients alike will closely monitor the review process as the industry moves toward a new era of precision immuno-oncology.
Source: Genentech press release
